The future of multiple sclerosis therapies: Redesigning multiple sclerosis clinical trials in a new therapeutic era

Henry F. McFarland, S. C. Reingold

Research output: Contribution to journalArticlepeer-review

Abstract

Due to past success in testing and gaining regulatory approval for a variety of therapies in multiple sclerosis (MS), the conduct of future clinical trials has become increasingly problematic. An international workshop has met to discuss the issues facing the MS clinical trial community and to examine possible new strategies for the design of trials. Particular focus has been placed on trials that either avoid the use of a placebo because of ethical considerations or on designs that allow new therapies to be studied more rapidly or with fewer patients than needed in a conventional placebo-controlled trial. The discussions resulting from the workshop should provide a basis for the examination and implementation of innovative clinical trial designs in MS.

Original languageEnglish (US)
Pages (from-to)669-676
Number of pages8
JournalMultiple Sclerosis
Volume11
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

Keywords

  • Clinical trials
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'The future of multiple sclerosis therapies: Redesigning multiple sclerosis clinical trials in a new therapeutic era'. Together they form a unique fingerprint.

Cite this